XMU-MP-3

• CAT Number: I015179
• CAS Number: 2031152-08-4
• Molecular Formula: C₂₇H₂₇F₃N₈O
• Molecular Weight: 536.55
• Purity: ≥95%
• Target: Apoptosis
• IUPAC Name: N-[3-[2-[(2,5-dimethylpyrazol-3-yl)amino]-8-methyl-5,7-dihydropyrimido[4,5-d]pyrimidin-6-yl]-4-methylphenyl]-3-(trifluoromethyl)benzamide
• InChI: InChI=1S/C27H27F3N8O/c1-16-8-9-21(32-25(39)18-6-5-7-20(11-18)27(28,29)30)12-22(16)38-14-19-13-31-26(34-24(19)36(3)15-38)33-23-10-17(2)35-37(23)4/h5-13H,14-15H2,1-4H3,(H,32,39)(H,31,33,34)
• InChIKey: MCEWMWAJAOMTBE-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)N3CC4=CN=C(N=C4N(C3)C)NC5=CC(=NN5C)C

XMU-MP-3（Cat No.:I015179）is a potent and selective inhibitor of the Hippo pathway kinases MST1 and MST2, which play critical roles in regulating cell growth, apoptosis, and organ size. By inhibiting these kinases, XMU-MP-3 promotes the activation of downstream effectors, such as YAP/TAZ, leading to increased cell proliferation and survival. This makes it a valuable tool for studying tissue regeneration, wound healing, and cancer research. XMU-MP-3 has shown potential in enhancing tissue repair and regeneration, offering therapeutic promise for conditions involving impaired tissue growth or damage.

Reference

[1]. Fu Gui, et al. A Non-Covalent Inhibitor XMU-MP-3 Overrides Ibrutinib-Resistant Btk C481S Mutation in B-cell Malignancies. Br J Pharmacol. 2019 Dec;176(23):4491-4509.